Dare Bioscience, Inc. current report, 12 April 2019

Dare Bioscience, Inc. - Form 8-K Summary

Business Context and Reporting Period

This Current Report (Form 8-K) was filed by Dare Bioscience, Inc. on April 12, 2019, covering events occurring on April 11, 2019. The company is an emerging growth company incorporated in Delaware.

Key Financial Metrics

The filing details the completion of an underwritten public offering of common stock. Key financial figures include:

  • Total Shares Issued: 5,261,250 shares (including over-allotment).
  • Public Offering Price: $1.10 per share.
  • Gross Proceeds: Approximately $5.8 million.
  • Net Proceeds: Approximately $5.2 million (after underwriting discounts and estimated offering expenses).

The filing does not provide data on revenue, profit, operating cash flow, margins, or existing debt levels.

Material Changes

The primary material event was the full exercise of the underwriters' over-allotment option to purchase an additional 686,250 shares. This action increased the total shares issued in the offering and the total capital raised compared to the initial announcement.

Outlook and Risks

The filing does not contain specific management guidance, forward-looking outlook statements, or a discussion of risks and contingencies beyond the standard disclosure of the offering completion.

Investor Verification Checklist

  • Verify the final number of shares outstanding post-offering.
  • Confirm the exact amount of net proceeds received after all closing expenses.
  • Review the company's use of proceeds as detailed in the related prospectus.
  • Check for any dilution impact on existing shareholders.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.